Bone Metabolism Biomarkers as Potential Diagnostic Tools for Non-Alcoholic Fatty Liver Disease: Findings from a Case–Control Study
DOI:
https://doi.org/10.31351/vol35iss3pp29-37Abstract
Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as a systemic condition affecting extrahepatic organs, including bone. Alterations in bone metabolism may occur early in the disease course. This study aimed to evaluate the diagnostic and prognostic relevance of selected bone metabolism markers osteocalcin, C-terminal telopeptide of type I collagen (CTX), and fibroblast growth factor 23 (FGF23) in NAFLD patients. A case-control study was conducted involving 45 NAFLD patients and 45 age-, sex-, and body mass index-matched healthy controls. Serum levels of osteocalcin, CTX, and FGF23 were measured using ELISA. The degree of hepatic steatosis was assessed by ultrasonography, while fibrosis risk was evaluated using the FIB-4 index. Statistical analyses included ROC curve analysis, correlation, and group comparisons. NAFLD patients showed significantly lower osteocalcin and higher CTX and FGF23 compared with controls (p < 0.001). ROC analysis revealed strong diagnostic accuracy for osteocalcin (AUC = 0.976, sensitivity 97.8%, specificity 86.7%), CTX (AUC = 0.894, sensitivity 91.1%, specificity 93.3%), and FGF23 (AUC = 0.922, sensitivity 97.8%, specificity 84.4%). While these markers correlated with liver enzymes and fibrosis indices, they were not significantly associated with steatosis or fibrosis severity. In conclusion, alterations in osteocalcin, CTX, and FGF23 suggest a metabolic link between liver and bone. These markers may serve as promising non-invasive diagnostic biomarkers for NAFLD, but larger studies with histological validation are needed.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Habibullah M, Jemmieh K, Ouda A, Haider MZ, Malki MI, Elzouki AN. Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies. Front Med (Lausanne). 2024 Jan 23;11:1291501.
Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023 Apr 1;77(4):1335-47.
Sabah YH, Hassan F. The Link between NAFLD and Colorectal Cancer: Insights from Liver Function Enzymes and Serum Biomarkers in a Case-Control Study. Journal of Biotechnology Research Center. 2025 Jun 3;19(2):96-103.
Alrubaie AL, Rezqallah RE, Ahmed MA, Musa S, Al-Qanbar MH. Correlation between Body Mass Index and Nonalcoholic Fatty Liver Disease. AL-Kindy College Medical Journal. 2022 May 5;18(1):56-9.
Abdul Sattar A, T. Al-Sa'adi Wa. Evaluation of Adiponectin, Irisin, Vitamin D Levels and Their Relation in Iraqi Patients with Non alcoholic Fatty Liver Disease. Ibn AL-Haitham Journal For Pure and Applied Sciences. 2023 Apr 20;36(2):241-50.
ShojaeiBaghini M, Fattahi M, Mohammadi M, Hamzavi F. Risk Factors for Non-alcoholic Fatty Liver Disease from the Perspective of Medical Professionals: A Systematic Review and Expert Opinion. Middle East J Dig Dis. 2025 Jan;17(1):54-9.
Abdulrahman NM, Shatha Hussein A. Polymorphism of Vitamin D Receptor Gene Taq1 (rs731236) and its Effect on Bone Turnover Markers in Iraqi Postmenopausal Osteoporotic Women After Vitamin D Supplementation. Iraqi Journal of Pharmaceutical Sciences. 2025 Jun 25;34(2):175-83.
Savari F, Mard SA. Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment. Heliyon. 2024 Mar 25;10(7):e28468.
Zhang CY, Yuan WG, He P, Lei JH, Wang CX. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol. 2016 Dec 28;22(48):10512-22.
Somnay K, Wadgaonkar P, Sridhar N, Roshni P, Rao N, Wadgaonkar R. Liver Fibrosis Leading to Cirrhosis: Basic Mechanisms and Clinical Perspectives. Biomedicines. 2024 Sep 30; 12(10):2229.
Sanyal AJ, Castera L, Wong VW. Noninvasive Assessment of Liver Fibrosis in NAFLD. Clin Gastroenterol Hepatol. 2023 Jul;21(8):2026-39.
Wang J, Qin T, Sun J, Li S, Cao L, Lu X. Non-invasive methods to evaluate liver fibrosis in patients with non-alcoholic fatty liver disease. Front Physiol. 2022 Dec 14;13:1046497.
Kazi IN, Kuo L, Tsai E. Noninvasive Methods for Assessing Liver Fibrosis and Steatosis. Gastroenterol Hepatol (NY). 2024 Jan;20(1):21-9.
AlKenany Q, K. Rasheed M, A. J. AlKazraj K. The Predictive Role of Osteopontin Level in Patients with Type 2 Diabetes Mellitus without Fatty Liver Disease. Journal of the Faculty of Medicine Baghdad. 2024 Apr 1;66(1):93-8.
Khammas I, Ali Abdulhussain K, Bassam F. Serum Levels of Advanced Oxidation Protein Products and some Liver Function Markers in Chronic Myeloid Leukemia-Chronic Phase Patients Receiving Imatinib or Nilotinib. Iraqi Journal of Pharmaceutical Sciences. 2025 Jun 25;34(2):40-6.
Zhao J, Lei H, Wang T, Xiong X. Liver-bone crosstalk in non-alcoholic fatty liver disease: Clinical implications and underlying pathophysiology. Front Endocrinol (Lausanne). 2023 Mar 10;14:1161402.
Danford CJ, Trivedi HD, Bonder A. Bone Health in Patients With Liver Diseases. J Clin Densitom. 2020 Apr-Jun;23(2):212-22.
Vachliotis ID, Anastasilakis AD, Goulas A, Goulis DG, Polyzos SA. Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications. Diabetes Obes Metab. 2022 Sep;24(9):1702-20.
Hassan AM, Haridy MA, Shoaeir MZ, Abdel-Aziz TM, Qura MK, Kenawy EM, et al. Non-alcoholic fatty liver disease is associated with decreased bone mineral density in upper Egyptian patients. Sci Rep. 2023 Mar 16;13(1):4353.
Drapkina OM, Elkina AY, Sheptulina AF, Kiselev AR. Non-Alcoholic Fatty Liver Disease and Bone Tissue Metabolism: Current Findings and Future Perspectives. Int J Mol Sci. 2023 May 8;24(9):8445.
Sun Y, Dai W, Liang Y, Yang P, Yang Q, Liang M, Xia N. Relationship between nonalcoholic fatty liver disease and bone mineral density in adolescents with obesity: a meta-analysis. Diabetes Metab Syndr Obes. 2019 Jan 30;12:199-207.
Piñar-Gutierrez A, García-Fontana C, García-Fontana B, Muñoz-Torres M. Obesity and Bone Health: A Complex Relationship. Int J Mol Sci. 2022 Jul 27;23(15):8303.
Zhou R, Guo Q, Xiao Y, Guo Q, Huang Y, Li C, Luo X. Endocrine role of bone in the regulation of energy metabolism. Bone Res. 2021 May 20;9(1):25.
Zamil A, Amin S. Insulin Resistance in Association with Metabolic Syndrome in Wasit University Students in Iraq. Iraqi Journal of Pharmaceutical Sciences. 2023 Sep 27;32(2):65-73.
Amarasekara DS, Yu J, Rho J. Bone Loss Triggered by the Cytokine Network in Inflammatory Autoimmune Diseases. J Immunol Res. 2015;2015:832127.
Bonaccorsi G, Piva I, Greco P, Cervellati C. Oxidative stress as a possible pathogenic cofactor of post-menopausal osteoporosis: Existing evidence in support of the axis oestrogen deficiency-redox imbalance-bone loss. Indian J Med Res. 2018 Apr;147(4):341-51.
Fairooz Aj, Jamal My, Alkhalidi Nm. Therapeutic Effects of Vitamin E in Non-alcoholic Fatty Liver Disease: An Open-Labeled Clinical Trial. Iraqi Journal of Pharmaceutical Sciences. 2022 Dec 24;31(2):135-43.
Tariq S, Baig M, Valjevac A. Editorial: Osteoporosis and adipokines: the potential for future treatment. Front Endocrinol (Lausanne). 2024 Apr 10;15:1405412.
Filip R, Radzki RP, Bieńko M. Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis. Clin Interv Aging. 2018 Oct 4;13:1879-91.
Li C, Cui Y, Zhou W, Zhang Y, Huang X, Yu F. Bone Turnover Markers in Adults with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Int J Endocrinol. 2023 Jul 19;2023:9957194.
Xia M, Rong S, Zhu X, Yan H, Chang X, Sun X, et al. Osteocalcin and Non-Alcoholic Fatty Liver Disease: Lessons From Two Population-Based Cohorts and Animal Models. J Bone Miner Res. 2021 Apr;36(4):712-728.
Deng H, Dai Y, Lu H, Li SS, Gao L, Zhu DL. Analysis of the correlation between non-alcoholic fatty liver disease and bone metabolism indicators in healthy middle-aged men. Eur Rev Med Pharmacol Sci. 2018 Mar;22(5):1457-1462.
Xie Y, Su N, Yang J, Tan Q, Huang S, Jin M, et al. FGF/FGFR signaling in health and disease. Signal Transduct Target Ther. 2020 Sep 2;5(1):181.
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-402.
Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002 Sep;123(3):745-50.
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006 Jun;43(6):1317-25.
Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, et al. FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. Life (Basel). 2021 Feb 14;11(2):143.
Huang Q, Guo J, Zhao H, Zheng Y, Zhang Y. The associations of alcoholic liver disease and nonalcoholic fatty liver disease with bone mineral density and the mediation of serum 25-Hydroxyvitamin D: A bidirectional and two-step Mendelian randomization. PLoS One. 2023 Oct 19;18(10):e0292881.
Mantovani A, Dauriz M, Gatti D, Viapiana O, Zoppini G, Lippi G, Byrne CD, Bonnet F, Bonora E, Targher G. Systematic review with meta-analysis: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density. Aliment Pharmacol Ther. 2019 Feb;49(4):375-88.
Hansen SG, Wernberg CW, Grønkjær LL, Jacobsen BG, Caterino TD, Krag A, Juhl CB, Lauridsen MM, Shanbhogue VV. Are Nonalcoholic Fatty Liver Disease and Bone Mineral Density Associated? - A Cross-Sectional Study Using Liver Biopsy and Dual-Energy X-Ray Absorptiometry. JBMR Plus. 2023 Jan 11;7(3):e10714.
Guedes JAC, Esteves JV, Morais MR, Zorn TM, Furuya DT. Osteocalcin improves insulin resistance and inflammation in obese mice: Participation of white adipose tissue and bone. Bone. 2018 Oct;115:68-82.
Wu XL, Zou XY, Zhang M, Hu HQ, Wei XL, Jin ML, Cheng HW, Jiang S. Osteocalcin prevents insulin resistance, hepatic inflammation, and activates autophagy associated with high-fat diet-induced fatty liver hemorrhagic syndrome in aged laying hens. Poult Sci. 2021 Jan;100(1):73-83.
He X, Shen Y, Ma X, Ying L, Peng J, Pan X, Bao Y, Zhou J. The association of serum FGF23 and non-alcoholic fatty liver disease is independent of vitamin D in type 2 diabetes patients. Clin Exp Pharmacol Physiol. 2018 Jul;45(7):668-674.
Nysather J, Kaya E, Manka P, Gudsoorkar P, Syn WK. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk. Adv Kidney Dis Health. 2023 Jul;30(4):315-335.
Hanudel M, Jüppner H, Salusky IB. Fibroblast growth factor 23: fueling the fire. Kidney Int. 2016 Nov;90(5):928-930.
Downloads
Published
License
Copyright (c) 2026 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
